Prevention of Transmission Pillar
A Cost Analysis of the Effectiveness of Rapid Identification and Susceptibility Testing of Positive Blood Cultures
Principal Investigator: Daniel Gregson, MD
Co-Investigator(s): Elissa Rennert-May, MD; Ranjani Somayaji, MD; John Conly, MD; Jenine Leal, PhD; Bruce Dalton, PharmD
Trainees: Kwadwo Mponponsuo, MD
The focus of this project is to determine the costs and outcomes in the management of bacterial bloodstream infections along with the effect of rapid diagnostic tests on these factors.
Why is This Important?
Bacteremia is common in hospitalized patients with an increasing incidence of disease caused by drug-resistant pathogens resulting in high costs of hospitalization and poor outcomes. Rapid diagnostic tests have been utilized to provide faster identification and susceptibility of pathogens leading to a reduction in time to appropriate therapy.
An understanding as to whether or not rapid diagnostic tests will lead to a reduction in time to appropriate therapy, reduced costs, and improved patient outcomes.
Clinical outcomes such as mortality, length of hospitalization, antimicrobial usage, and quality-adjusted life years will be evaluated between the two groups.
Leveraged Sources of Support
- UofC Department of Medicine- Infrastructure
- Alberta Public Laboratories Infrastructure and Database
- One Health Consortium - Funding
Knowledge & Technology: Exchange and Exploitation
- Evaluation of which rapid diagnostic tests to fund.
- Targeted antimicrobial therapy for those with drug-resistant bacteremia
- Informing and improving patient care and outcome
Highly Qualified Personnel
- 1 Medical micobiologist
- 3 Early investigator research scientists, including expertise in health economics and economic analyses
- 1 Infectious Diseases fellow
- 1 Clinical pharmD
- 1 Biostatistician/analyst